Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Blood (2024) 144 (3): 262–271.

https://doi.org/10.1182/blood.2024023944

Published: 2024

Includes: Supplemental data

Journal Articles

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Blood (2023) 142 (Supplement 1): 979.

https://doi.org/10.1182/blood-2023-188788

Published: 2023

Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Blood (2022) 140 (Supplement 1): 2302–2305.

https://doi.org/10.1182/blood-2022-165217

Published: 2022

Journal Articles

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Louise Roulin, Elsa Poullot, Paul Blanc-Durand, Cyrielle Robe, Francois Lemonnier, Fabien Le Bras, Romain Gounot, Karim Belhadj, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Sebastien Mule, Christiane Copie Bergman, Thierry Molina, Marie Helene Delfau Larue, Emmanuel Itti, Philippe Gaulard, Corinne Haioun

Blood (2021) 138 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2021-152627

Published: 2021

Journal Articles

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

Blood (2021) 138 (Supplement 1): 379.

https://doi.org/10.1182/blood-2021-149600

Published: 2021

Journal Articles

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Christiane Copie Bergman, MDPhD, Elodie Bohers, PhD, Peggy Dartigues-Cuillères, MD, Pierre-Julien Viailly, Philippe Ruminy, PhD, Vinciane Marchand, Marie-Helene Delfau-Larue, Corinne Haioun, MDPhD, Cyrielle Robe, Elsa Poullot, MD, Steven Le Gouill, MD PhD, Yannick Le Bris, PharmD, Céline Bossard, MD, Anne Moreau, MD, Vincent Ribrag, MD, Valérie Camara-clayette, PhD, Cyril Quivoron, PhD, Gilles Salles, MDPhD, Sophie Cotteret, MD PhD, Pierre Sujobert, MD PhD, Alexandra Traverse-Glehen, MD PhD, Claire Mauduit, Pascaline Etancelin, Sarah Huet, Liana Veresezan, MD, Krimo Bouabdallah, MD, Marie Parrens, MD, Audrey Gros, PhD, Samuel Amintas, David Sibon, MD PhD, Ludovic Lhermitte, MD PhD, Thomas Steimle, Sophie Kaltenbach, Bettina Fabiani, MD, Camille Laurent, MD PhD, Barbara Burroni, Laurent Martin, MD PhD, Thierry Jo Molina, MDPhD, Lysa LYSARC study group, Fabrice Jardin, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141953

Published: 2020

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Mary B. Callanan, PhD, Elizabeth Macintyre, PhD MD, Marie-Helene Delfau-Larue, MD PhD, Catherine Thieblemont, MD PhD, Lucie Oberic, MD, Emmanuel Gyan, MD PhD, Krimo Bouabdallah, MD, Rémy Gressin, MD, Gandhi Damaj, MD PhD, Olivier Casasnovas, MD, Vincent Ribrag, MD, Samuel Griolet, Bénédicte Burlet, Benjamin Tournier, PhD, Sylviane Ragot, M.Sc, Caroline Bodet-Milin, Olivier Hermine, Steven Le Gouill, MD PhD

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-140457

Published: 2020

Journal Articles

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Blood (2020) 135 (5): 360–370.

https://doi.org/10.1182/blood.2019001904

Published: 2020

Includes: Supplemental data

Journal Articles

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Blood (2019) 134 (Supplement_1): 4122.

https://doi.org/10.1182/blood-2019-123259

Published: 2019

Journal Articles

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network

Sietse M. Aukema, Eva Hoster, Andreas Rosenwald, Danielle Canoni, Marie-Hélène Delfau-Larue, Grzegorz Rymkiewicz, Christoph Thorns, Sylvia Hartmann, Hanneke Kluin-Nelemans, Olivier Hermine, Martin Dreyling, Wolfram Klapper

Blood (2018) 131 (4): 417–420.

https://doi.org/10.1182/blood-2017-07-797019

Published: 2018

Includes: Supplemental data

Journal Articles

P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group

Danielle Canioni, MD, Barbara Burroni, MD, Anne Moreau, MD, Alexandra traverse-Glehen, MD PhD, Antoine Martin, MD PhD, Remy Gressin, MD, Vincent Ribrag, MD, Catherine Thieblemont, MD PhD, Marie-Helene Delfau-Larue, Elizabeth A. Macintyre, PhD FRCP, FRCPath, Mary Callanan, MD, Steven Le Gouill, MDPhD, Olivier Hermine, MD PhD

Blood (2017) 130 (Supplement 1): 4036.

https://doi.org/10.1182/blood.V130.Suppl_1.4036.4036

Published: 2017

Journal Articles

Somatic Mutation and Isotype Switch Events Outside Igv Gene Loci Provide New Evidence for a Role of Antigenic Challenge in Mantle Cell Lymphoma Etiology

Sandrine Roulland, Pharm.D., PhD, Nathalie Jouve, Agnes Bru, Marie-Helene Delfau-Larue, MD PhD

Blood (2015) 126 (23): 2647.

https://doi.org/10.1182/blood.V126.23.2647.2647

Published: 2015

Journal Articles

Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma

Marie-Helene Delfau-Larue, MD PhD, Isabelle Nel, PD, Axel VAN Der Gucht, MD, Gaelle Laboure, MD, Benjamin Verret, MD, Salma Hamdane, PD, Philippe Gaulard, MD PhD, Michel Meignan, MD PhD, Corinne Haioun, MD PhD, Christiane Copie-Bergman, MD PhD, Jehan Dupuis, MD, Emmanuel Itti, MD PhD

Blood (2015) 126 (23): 3872.

https://doi.org/10.1182/blood.V126.23.3872.3872

Published: 2015

Journal Articles

Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS)

Clémentine Sarkozy, MD, Sarah Huet, PharmD, PhD, Victoria Carlton, Alain Delmer, MD PhD, Fabrice Jardin, Marie-Helene Delfau-Larue, MD PhD, Malek Faham, Gilles Salles, MD PhD

Blood (2015) 126 (23): 2675.

https://doi.org/10.1182/blood.V126.23.2675.2675

Published: 2015

Journal Articles

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Marie-Hélène Delfau-Larue, Wolfram Klapper, Françoise Berger, Fabrice Jardin, Josette Briere, Gilles Salles, Olivier Casasnovas, Pierre Feugier, Corinne Haioun, Vincent Ribrag, Catherine Thieblemont, Michael Unterhalt, Martin Dreyling, Elizabeth Macintyre, Christiane Pott, Olivier Hermine, Eva Hoster

Blood (2015) 126 (5): 604–611.

https://doi.org/10.1182/blood-2015-02-628792

Published: 2015

Includes: Supplemental data

Journal Articles

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

Lionel Karlin, Jacques Bienvenu, PhD, Rene-Olivier Casasnovas, MD, Marie-Helene Delfau-Larue, MD PhD, Pierre Feugier, MD PhD, Jehan Dupuis, MD, Tioka Rabeony, Christophe Ferme, MD, Catherine Sebban, MD, Pierre Soubeyran, MD PhD, Guillaume Cartron, MD, Alain Delmer, MD PhD, Dominique Bordessoule, MD, Pauline Brice, MD, Thierry Lamy, MD PhD, Sami Bousseta, Hervé Tilly, MD PhD, Gilles Andre Salles, MD PhD

Blood (2014) 124 (21): 4430.

https://doi.org/10.1182/blood.V124.21.4430.4430

Published: 2014

Journal Articles

Minimal Residual Disease (MRD) By 8-Color Flow Cytometry (Flow-MRD) and IGH Clonospecific Quantitative PCR (ASO RQPCR) Reached Similar Performances for Evaluation of CLL Treatment in a Phase II Clinical Trial: Cross Validation of the Methods

Remi Letestu, MD PhD, Guillaume Cartron, MD, Stephane Lepretre, MD, Magali Le Garff-Tavernier, PharmD, PhD, Francoise Solly, MD, Lydia Campos, MD PhD, Michel Ticchioni, MD PhD, Claire Quiney, Abdelmalek Dahmani, Marouane Boubaya, Vincent Levy, MD PhD, Florence Cymbalista, MD, Marie-Helene Delfau-Larue, MD PhD

Blood (2014) 124 (21): 3307.

https://doi.org/10.1182/blood.V124.21.3307.3307

Published: 2014

Journal Articles

Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

Marie-Hélène Delfau-Larue, MD PhD, Klapper Wolfram, MDPhD, Francoise Berger, Fabrice Jardin, MD PhD, Josette Briere, MD, Catherine Thieblemont, MD PhD, Pierre Feugier, MD PhD, Corinne Haioun, MD, Gilles Andre Salles, MD PhD, Vincent Ribrag, MD, Rene-Olivier Casasnovas, MD, Michael Unterhalt, MD, Martin Dreyling, Christiane Pott, MD PhD, Elizabeth Macintyre, MD PhD, Olivier Hermine, MD PhD, Eva Hoster, PhD

Blood (2014) 124 (21): 1625.

https://doi.org/10.1182/blood.V124.21.1625.1625

Published: 2014

Journal Articles

MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

Christiane Pott, M..D, PhD, Elizabeth Macintyre, MD PhD, Marie-Helene Delfau-Larue, MD PhD, Vincent Ribrag, MD, Michael Unterhalt, MD, Michael Kneba, MD PhD, Wolfgang Hiddemann, MD, Martin Dreyling, MD PhD, Olivier Hermine, MD PhD, Eva Hoster, PhD

Blood (2014) 124 (21): 147.

https://doi.org/10.1182/blood.V124.21.147.147

Published: 2014

NARROW

Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial

Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Clinical, Immunophenotypic and Genetic Characteristics of Aggressive (non-Burkitt) B-Cell Lymphoma in a Real Life Cohort

Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network

P53 and P16 Protein Expression Have Prognostic Value in Mantle Cell Lymphomas in the Lyma Trial in the Lysa Group

Somatic Mutation and Isotype Switch Events Outside Igv Gene Loci Provide New Evidence for a Role of Antigenic Challenge in Mantle Cell Lymphoma Etiology

Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma

Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS)

High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma

Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study

Minimal Residual Disease (MRD) By 8-Color Flow Cytometry (Flow-MRD) and IGH Clonospecific Quantitative PCR (ASO RQPCR) Reached Similar Performances for Evaluation of CLL Treatment in a Phase II Clinical Trial: Cross Validation of the Methods

Rituximab and High-Dose Cytarabine Do Not Counteract the Adverse Prognostic Value of CDKN2A and TP53 Deletions in Autografted Mantle-Cell Lymphoma Patients. a European-MCL Network Study

MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only